TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01667692
Drug: clarithmycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
Study: NCT02925832
Drug: Proparacaine
Normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For anaesthetising conjunctiva
Study: NCT03841448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) matching volume of cemdisiran doses were administered SC.
Study: NCT01303783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
Study: NCT01020383
Drug: ReoPro®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Study: NCT03792919
Drug: Stop current treatment (anti-HBV neucleos(t)ides)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
Study: NCT01517100
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid Receptor 1 antagonist
Study: NCT00901628
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg intraoperative periarticular injection
Study: NCT01403311
Drug: 5-Aminolevuline Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
Study: NCT00901628
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 microgram (1:1000) intraoperative periarticular injection
Study: NCT04478266
Drug: Amcenestrant-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Study: NCT04478266
Drug: SAR439859
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Study: NCT00391729
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
Study: NCT00391729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo QD, BID for 4-6 weeks
Study: NCT01021995
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops, 0.9 ml tid for 4 months
Study: NCT02465645
Drug: Carvedilol + Simvastatin
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01613534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon plasma coagulation treatment followed by placebo administration for four weeks
Study: NCT04594343
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Study: NCT04594343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Study: NCT02389985
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01501799
Drug: Placebo (Vehicle Gel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
Study: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
Study: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
Study: NCT04447040
Drug: Acetaminophen/naproxen sodium Dose D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
Study: NCT04447040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered as a single two-tablet dose.
Study: NCT02506790
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00257608
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT00292396
Drug: Anti IL-12 monoclonal antibody/ABT-874
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Arm Description for intervention description and details.
Study: NCT00292396
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 doses
Study: NCT02516241
Drug: MEDI4736 (Durvalumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03907280
Drug: BI 1265162 (R)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: concentrate for i.v. solution
Study: NCT01854658
Drug: GP MDI (PT001)
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI administered as two puffs BID
Study: NCT01854658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00685542
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02597868
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
Study: NCT00704418
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00704418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT02537028
Drug: MSC2364447C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
Study: NCT02537028
Drug: MSC2364447C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
Study: NCT02537028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
Study: NCT04618913
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin
Study: NCT03835871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: placebo
Study: NCT03835871
Drug: 400 µg per day Beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Study: NCT03835871
Drug: 200 µg per day Beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 200 µg HFA per day
Study: NCT03835871
Drug: 100 µg per day Beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Beclomethasone 100 µg HFA per day
Study: NCT06187584
Drug: Hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen 0.15mg/kg PO q6
Study: NCT06187584
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/kg PO q6 hours
Study: NCT06187584
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/kg PO q6 hours
Study: NCT03825757
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT01216111
Drug: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
Study: NCT02174939
Drug: Dummy Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice per day for 12 weeks
Study: NCT03110926
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Chemotherapy
Study: NCT01182610
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5FU 225mg/m2/day on Days 1-15 and 22-36
Study: NCT00338247
Drug: lapatinib + capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT03138603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
Study: NCT02010242
Drug: GKT137831
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
Study: NCT02010242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
Study: NCT01190683
Drug: cholecalciferol and calcium carbonate
Normalized name: calcium carbonate / cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
Study: NCT02638831
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
Study: NCT04418674
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this group, the patients will receive fentanyl at 1.5mcg/kg intavenously.
Study: NCT02495831
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg single dose
Study: NCT02495831
Drug: Diclofenac sodium and safinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg single dose and safinamide 200 mg single dose
Study: NCT01565720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03950570
Drug: ORIN1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
Study: NCT01464827
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450 tablets
Study: NCT01464827
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-333 tablets
Study: NCT01464827
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-267 tablets
Study: NCT03463044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00544765
Drug: TAC
Normalized name: TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
Study: NCT00810732
Drug: Open
Normalized name: Pyopen
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
Study: NCT00810732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for sitaxsentan, orally administered once daily (double blind arm)
Study: NCT03618550
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT04641143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo - 2 140mg capsules QD from week two through week ten.
Study: NCT01095003
Drug: Vinflunine plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Study: NCT01095003
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Study: NCT01633827
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
Study: NCT01633827
Drug: Sedative
Normalized name: Sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
Study: NCT03650582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: NCT00268346
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD1839 treatment will be taken once a day PO, every day about the same time
Study: NCT00176904
Drug: Busulfan, Cyclophosphamide, Antithymocyte Globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study: NCT04604184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01838902
Drug: DHA-PPQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a 3 day course of DHA-PPQ
Study: NCT01838902
Drug: PQ (0.75)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of PQ at 0.75mg base/kg body weight
Study: NCT01838902
Drug: PQ (0.4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of PQ at 0.4mg base/kg body weight
Study: NCT01838902
Drug: PQ (0.2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of PQ at 0.2mg base/kg body weight
Study: NCT01711021
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Study: NCT04725422
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT04725422
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Study: NCT01784133
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04576325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
Study: NCT02554695
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous saline injection
Study: NCT01409434
Drug: Oral Glucose Tolerance Test
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
Study: NCT00293215
Drug: CMD-193
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMD-193 was administered as an IV infusion over 60 (± 5) minutes.
Study: NCT03924414
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
Normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
Study: NCT00294723
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride placebo, 8mg capsule
Study: NCT00294723
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, 200 mcl
Study: NCT00294723
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, 300 mcl
Study: NCT00193908
Drug: Sorbolene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
Study: NCT02472392
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparitor
Study: NCT00062140
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04161144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
Study: NCT02271555
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
Study: NCT03179527
Drug: Anti-Platelet Drugs
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Including aspirin and clopidogrel, etc
Study: NCT04472975
Drug: Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with MS exposed to one or more DMDs (beta-interferon, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab, daclizumab or ocrelizumab; regardless of dose, frequency or duration of treatment) between 1st January 1996 and 31st March 2018 in five Canadian provinces.
Study: NCT03179527
Drug: Lipid Regulating Drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including statins
Study: NCT03179527
Drug: Coronary Vasodilator
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including nitrates
Study: NCT03179527
Drug: Shuanghe Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Study: NCT02827903
Drug: Metformin + Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: Metformin + Rosuvastatin,
Study: NCT02827903
Drug: placebo + Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: placebo + Rosuvastatin
Study: NCT04079218
Drug: Estradiol Vaginal Insert
Normalized name: estradiol Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
Study: NCT04568421
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory and/or immunosuppressive drugs according to the indication of the treating physician
Study: NCT01649050
Drug: BGG492
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01649050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04498390
Drug: LY3493269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04498390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04512950
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
Study: NCT04512950
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
Study: NCT03917459
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Study: NCT03917459
Drug: LCZ696 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
Study: NCT03905291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT03449082
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.5cc